Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
25 Nov 2024: Adcendo raises $135m as ADC funding frenzy continues
- Adcendo raised $135 million in funding to advance its portfolio of first-in-class ADCs into clinical trials
- Company’s ADC candidate, ADCE-D01, received FDA clearance for an IND application for a Phase 1/2 first-in-human trial targeting the UPABAR receptor in patients with metastatic and unresectable soft tissue sarcoma (STS)
- Adcendo signed a $1 billion agreement with Multitude Therapeutics for the ex-China rights to ADCE-T02, a preclinical ADC candidate, with plans to begin a Phase 1 trial in Australia by Q4 2024
- The company is also advancing two other ADC candidates, ADCE-B05 and A0401, with undisclosed targets
